
BioCardia Inc (BCDA) - Product Pipeline Analysis, 2023 Update
Description
Summary
BioCardia Inc (BioCardia) is a regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The company develops biotherapeutic candidates that include a CardiAMP cell therapy system, an autologous minimally processed bone marrow cells, an allogeneic off-the-shelf mesenchymal stem cell product candidate for ischemic systolic heart failure. Its CardiAMP cell therapy system comprises cell potency screening test, a point-of-care cell processing platform, and a biotherapeutic delivery system. BioCardia also offers catheters for use in the delivery of therapeutic agents directly to the heart and guiding catheters for use in peripheral and coronary vasculature and chambers of the heart. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company BioCardia Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
34 Pages
- BioCardia Inc Company Overview
- BioCardia Inc Company Snapshot
- BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
- BioCardia Inc – Pipeline Analysis Overview
- BioCardia Inc - Key Facts
- BioCardia Inc - Major Products and Services
- BioCardia Inc Pipeline Products by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc Pipeline Products Overview
- CardiALLO - Ischemic Heart Failure
- CardiALLO - Ischemic Heart Failure Product Overview
- CardiAMP - Chronic Myocardial Ischemia
- CardiAMP - Chronic Myocardial Ischemia Product Overview
- CardiAMP - Chronic Myocardial Ischemia Clinical Trial
- CardiAMP - Heart Failure
- CardiAMP - Heart Failure Product Overview
- CardiAMP - Heart Failure Clinical Trial
- CardiAMP - Post Acute Infarction
- CardiAMP - Post Acute Infarction Product Overview
- Fusion Imaging System
- Fusion Imaging System Product Overview
- Helix Transendocardial Delivery System
- Helix Transendocardial Delivery System Product Overview
- Helix Transendocardial Delivery System Clinical Trial
- BioCardia Inc - Key Competitors
- BioCardia Inc - Key Employees
- BioCardia Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- BioCardia Inc, Recent Developments
- Jul 15, 2021: BioCardia announces Japanese patent on imaging system for targeting cardiac therapies
- Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific
- Mar 12, 2020: Biocardia announces timing for Prespecified Data Safety Monitoring Board Report on Pivotal Cardiamp Heart Failure Trial
- Jan 14, 2020: BioCardia announces FDA clearance of Morph DNA Deflectable Guide Catheter
- Jan 08, 2020: BioCardia announces new U.S. patent covering CardiAMP cell therapy and issuance of two Asian patents covering Radial Artery approach for Cardiac Cell and Gene Therapy Delivery
- Oct 08, 2019: BioCardia receives CE Mark renewal for Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter through May 2024
- Oct 01, 2019: BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures
- Sep 16, 2019: BioCardia announces positive DSMB recommendation to continue phase 3 pivotal CardiAMP heart failure study as planned
- Jun 12, 2019: BioCardia announces issuance of Chinese patent for image-guided biotherapeutic delivery
- May 23, 2019: Acute Myocardial Infarction patients treated early with cell therapy delivered with BioCardia's HElix Endocardial Delivery System improved in ejection fraction and NYHA class
- Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
- BioCardia Inc Pipeline Products by Equipment Type
- BioCardia Inc Pipeline Products by Indication
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc, Key Facts
- BioCardia Inc, Major Products and Services
- BioCardia Inc Number of Pipeline Products by Development Stage
- BioCardia Inc Pipeline Products Summary by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc Ongoing Clinical Trials Summary
- CardiALLO - Ischemic Heart Failure - Product Status
- CardiALLO - Ischemic Heart Failure - Product Description
- CardiAMP - Chronic Myocardial Ischemia - Product Status
- CardiAMP - Chronic Myocardial Ischemia - Product Description
- CardiAMP - Chronic Myocardial Ischemia - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients with Refractory Angina Pectoris and Chronic Myocardial Ischemia: CardiAMP CMI Trial
- CardiAMP - Heart Failure - Product Status
- CardiAMP - Heart Failure - Product Description
- CardiAMP - Heart Failure - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Post Myocardial Infarction Heart Failure: CardiAMP Heart Failure Trial
- CardiAMP - Post Acute Infarction - Product Status
- CardiAMP - Post Acute Infarction - Product Description
- Fusion Imaging System - Product Status
- Fusion Imaging System - Product Description
- Helix Transendocardial Delivery System - Product Status
- Helix Transendocardial Delivery System - Product Description
- Helix Transendocardial Delivery System - A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process, and Injected in Patients with an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% after PTCA and Stent(s) Implantation Versus Standard of Care
- Helix Transendocardial Delivery System - Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)
- Helix Transendocardial Delivery System - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Post Myocardial Infarction Heart Failure: CardiAMP Heart Failure Trial
- BioCardia Inc, Key Employees
- BioCardia Inc, Subsidiaries
- Glossary
- List of Figures
- BioCardia Inc Pipeline Products by Equipment Type
- BioCardia Inc Pipeline Products by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.